Management Team
Genomic Health´s management team has extensive experience in a variety of cutting-edge technical fields including the molecular diagnostics, information technology, biotechnology, pharmaceutical and genomic industries. Team members have demonstrated continued success in starting businesses, researching and developing novel drugs, launching products, building successful organizations and delivering value to shareholders.
- Randal W. Scott, Ph.D., Executive Chairman of the Board
- Kimberly J. Popovits, President & Chief Executive Officer
- G. Bradley Cole, Chief Operating Officer
- Joffre B. Baker, Ph.D., Chief Scientific Officer
- Steven Shak, M.D., Chief Medical Officer
- Dean L. Schorno, Chief Financial Officer
- Paul Aldridge, Ph.D., Senior Vice President and Chief Information Officer
- David Logan, Executive Vice President, Worldwide Commercialization
- Kathy Hibbs, Senior Vice President & General Counsel
- Laura Leber, Senior Vice President, Corporate Communications
Randal W. Scott, Ph.D., Executive Chairman of the Board
"Genomic Health is more than just a business—it is our quest to make a difference by helping friends and loved ones manage a challenging disease. The company was founded with a focus on cancer because we believe there is an immediate opportunity to impact the quality of care for cancer patients and their families."
"Our first diagnostic test, Oncotype DX, was developed to improve the quality of treatment decisions for women with breast cancer. We believe this is a significant advance and the beginning of a whole new approach to understanding and treating cancer at the molecular level. We believe that correlating genomic information with clinical outcomes and making that information available to individual patients and their healthcare providers can have a profound effect on the quality of care. That is why we conducted multiple large clinical studies with world-renowned clinical research groups to validate Oncotype DX."
"Our passion is to combine our collective experience in the scientific and business worlds in building a successful company, as measured by the difference we make for cancer patients. We believe that putting the patient´s healthcare interests first is the core strength of our business, and that nothing could be more rewarding than knowing that we can impact clinical decision making for cancer patients."
Considered a pioneer in the field of personalized medicine, Randy Scott, Ph.D. has served as Executive Chairman since 2009 and Chairman and Chief Executive Officer from 2000 through 2009. Under Randy’s leadership, Genomic Health developed and launched two revolutionary cancer diagnostics tests. Prior to being one of the founders of Genomic Health, Randy was also a founder of Incyte Corporation, a genomic information company, and provider of integrated platforms of genomic technologies designed to aid in the understanding of the molecular basis of disease. At Incyte Randy served in various roles from 1991 through 2000, including Chairman of the Board, President and Chief Scientific Officer. Before joining Incyte, Randy served as the Senior Director of Research at Invitron Corporation; a global biotechnology tools company. Randy holds a Bachelor of Science degree in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas. Randy is a prominent thought leader in the genomics and sequencing space and has been a featured speaker at events globally. Randy is the author of over 40 publications, 20 patents, and is the recipient of numerous awards which highlight his leadership in the personalized medicine space, including Distinguished Alumni Awards from The University of Kansas and Emporia State University, the Genome Technology Magazine 2001 All-Star award, and the Forbes Biotech’s Top 25 Influential Insiders in 1999. In 1997, he received the Ernst & Young/NASDAQ Silicon Valley Entrepreneur of the Year for Life Sciences award.
Kimberly J. Popovits, President & Chief Executive Officer
"Like many of my colleagues, it is my personal experience with cancer that drives my passion to change the way we diagnose and treat this complex disease that touches so many lives. As we gain greater understanding of the biology of cancer, we have an opportunity and a responsibility to develop tools that arm both physicians and patients with personalized genomic information to individualize the treatment of a patient´s disease. With the advent of biologics and new targeted therapeutics, the menu of treatment options for patients with cancer is growing. It is our mission to develop tests that employ the biology of an individual´s specific tumor to help physicians select appropriate treatments from this expanding menu. We are entering an era where we have the information and means to transform "one-size-fits-all" medicine to a world where treatment is truly personalized. We remain steadfast in our mission to provide cancer patients with access to information that can empower them to better manage their disease. Oncotype DX is the beginning. Our commitment is to set no limit on the end."
Committed to changing the paradigm of cancer care, Kim Popovits has served as President and Chief Executive Officer since 2009 and as President and Chief Operating Officer since 2002. Prior to joining Genomic Health, Kim served in various roles at Genentech, Inc., a biotechnology company, dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Most recently at Genentech, Kim served as Senior Vice President, Marketing and Sales from 2001 to 2002, and as Vice President, Sales from 1994 to 2001. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Kim served as division manager for American Critical Care, a division of American Hospital Supply. Kim holds a Bachelor of Arts degree in Business from Michigan State University. Kim currently serves on the board for BayBio, Northern California's life science association, which supports the regional bioscience community through advocacy, enterprise support, and enhancement of research collaboration. Kim is also the President of The Coalition for 21st Century Medicine, whose mission is to improve the quality of healthcare by encouraging research, development and commercialization of innovative diagnostic technologies that will personalize patient care, improve patient outcomes and reduce healthcare costs. Kim’s contributions to science and the biotechnology industry have been acknowledged by multiple organizations including, being named as the Woman of the Year in 2008 by the Women Health Care Executives and as one of the Most Influential Women in the Bay Area by The San Francisco Business Times from 2006 - 2011.
G. Bradley Cole, Chief Operating Officer
"Success is defined many times in life as doing something very well and sometimes only one thing. That can be true in business as well, and we have chosen treatment for patients with cancer as a singular focus by which to measure success. In doing so we have the opportunity to do the right thing very well for the benefit of medicine, patients, physicians, payers and the healthcare system overall. Having seen both family members and friends die from cancer in recent years, I can think of no better way to spend my day than helping others who will be faced with similar circumstances in the future.”
Steering the company through their initial public offering in 2005 and seeing the company make their first full year of profit in 2010; Brad Cole has served as Chief Operating Officer since 2009. Prior to his position as Chief Operating Officer, Brad was the Chief Financial Officer & Executive Vice President from 2004 until 2008. Before joining Genomic Health, Brad served in various positions at Guidant Corporation, a designer and developer of cardiovascular medical products. At Guidant, Brad served as Vice President, Finance and Business Development for the Endovascular Solutions Group from 2001 until 2004. Prior to that, he served as Vice President and General Manager of the Vascular Surgery Business Unit of Guidant. Brad was Vice President, Finance and Chief Financial Officer of Endovascular Technologies, Inc., a publicly traded medical device company acquired by Guidant Corporation in 1997. Previously, Brad was Vice President and Chief Financial Officer of Applied Biosystems, a publicly traded life sciences company. Brad holds a Bachelor of Science degree in Business from Biola University and an MBA from San Jose State University.
Joffre B. Baker, Ph.D., Chief Scientific Officer
"Genomic Health was founded to take advantage of developments in three areas:
1) decades of worldwide accumulation of scientific knowledge about cancer pathology at the cellular, molecular and genomic level
2) the continuous development of increasingly sensitive and precise laboratory technologies for quantifying genomic information
3) the development of scientific computing technology that permits the storage and analysis of vast amounts of genomic information
It is an exciting fact that progress in each of these three areas continues at a rapid pace. As a result, it is clear that the era of personalized medicine for cancer patients has not only arrived, but has a very bright future."
Since co-founding the company in 2000, Joff Baker, Ph.D. has served as Chief Scientific Officer and has overseen the research & development teams behind the breast, colon and prostate cancer programs at Genomic Health. Joff and his team are currently deploying Next Generation Sequencing technology and its application across all research initiatives in an effort to connect either gene mutations or expression profiles to clinical outcomes and provide additional personalized information to physicians and patients beyond that already available through the use of Oncotype DX®. Prior to cofounding Genomic Health in 2000, Joff served as Vice President for Research Discovery at Genentech, Inc., a biotechnology company, dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. From 1993 to 2000, Joff oversaw Research Discovery at Genentech, which included the Departments of Cardiovascular Research, Oncology, Immunology, Endocrinology and Pathology. From 1991 to 1993, he served as Genentech’s Director of Cardiovascular Research. Prior to joining Genentech, Joffre was a faculty member in the Department of Biochemistry at the University of Kansas. He holds a Bachelor of Science degree in Biology and Chemistry from the University of California, San Diego and a Ph.D. in Biochemistry from the University of Hawaii. Joff is the recipient of a NIH (National Institutes of Health) Research Career Development Award (1983 – 1988), and is the author of over 65 publications.
Steven Shak, M.D., Chief Medical Officer
"We urgently need new and more effective approaches to cancer diagnosis, treatment, and prevention.
In the 20th century, with few diagnostic tests to select the right treatment for individual cancers, physicians treated cancer with a “one size fits all” approach.
At Genomic Health, we have developed innovative, standardized, quantitative methods for profiling individual cancers. Cancer drugs can be (targeted) if we are able to discover and develop diagnostic tests to identify which patients are likely to benefit from them. We are using the same rigorous approach used in the clinical development and validation of the Oncotype DX Breast Cancer Assay to develop tests for other tumor types. We passionately believe that cancer molecular diagnostics will play an indispensable role in treatment planning for all cancer patients and will help turn cancer into a manageable, and ultimately preventable, disease. "
Dedicated to optimizing cancer treatment outcomes and bringing the patient voice into product development, Steve Shak, M.D. has served as Chief Medical Officer since 2000. Under Steve’s leadership Genomic Health used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype DX® breast cancer and colon cancer assays and has maintained an 80% product development success rate. Steve has been a leader in personalized medicine for more than two decades. Prior to co-founding Genomic Health in 2000, Steve served for 14 years in various roles in Discovery Research and Medical Affairs at Genentech, Inc., a biotechnology company dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Steve led the clinical team that gained approval for Herceptin®, a targeted biologic treatment for breast cancer. He also initiated the cancer clinical trials of the anti-angiogenesis agent, Avastin®. In addition, Steve discovered Pulmozyme®, a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease cystic fibrosis. Prior to joining Genentech, Steve was an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. Steve holds a Bachelor of Arts degree in Chemistry from Amherst College and an M.D. from New York University School of Medicine, and completed his post-doctoral training at University of California, San Francisco.
Dean L. Schorno, Chief Financial Officer
"Having been with the company from the early days in various roles at Genomic Health, from the clinical lab to my current position, I am proud to have helped deliver on the promise of personalized medicine in many capacities. It has been an honor to work with the incredibly talented employees of Genomic Health, who all share the singular focus of helping both patients and their families. The quality of our mission, people, clinical capabilities, and state-of-the-art laboratories, make Genomic Health a truly exceptional place to be. "
Having managed the launch and operations of Genomic Health’s clinical laboratory, as Vice President, Operations from 2004-2010, Dean brings unique perspective to his current role as Chief Financial Officer. Prior to his appointment to CFO in 2011; Dean oversaw financial affairs on a global basis as Senior Vice President, Finance From 2010 – 2011, and from 2001 through 2003, Dean led the finance group, as a Director and then Senior Director. Before joining Genomic Health, Dean founded and led a CPA and consulting firm. Dean also worked at an international accounting firm from 1985 to 1991. Dean holds a Bachelor of Science degree in Business Administration, from the University of California, Berkeley, and is a Certified Public Accountant.
Paul Aldridge, Ph.D., Senior Vice President and Chief Information Officer
"Genomic Health is at the forefront of the revolution in healthcare and personalized medicine. We focus on delivering information, unique and critical to every patient, into the hands of healthcare professionals and patients that will drive treatment decisions and improve individual outcomes. The work of delivering timely, complete and accurate information to physicians and patients is the core mission of a team of dedicated Information Technology professionals. Everyday, we look for ways to improve the standard of care for cancer patients worldwide."
Leading the innovation behind the Information Technology group at Genomic health, Paul Aldridge has served as the Senior Vice President and Chief Information Officer since 2009. Prior to joining Genomic Health, from 2003 to 2009, Paul served as Vice President, Global Information Technology at BIOGEN IDEC, Inc., a developer, manufacturer and marketer of biological products for the treatment of serious diseases with a focus on neurological disorders. Before that, Paul held several positions in Developmental Research and Information Technology at Pfizer Global R&D from 1991 to 2003. Paul is the author of three patents and over 40 scientific publications and presentations. He holds a Ph.D. and an M.S. in Analytical Chemistry from the University of Washington; and, a Bachelor of Science degree in Chemistry from California State University, Sacramento, and has served in the United States Coast Guard.
David Logan, Executive Vice President, Worldwide Commercialization
"When my journey at Genomic Health began very few physicians, insurance companies and, most importantly, patients knew there was a new test that could improve the way newly diagnosed breast cancer patients were treated. Our challenge (or as we say in sales, opportunity) was to educate and change treatment behavior, one physician, payor and patient at a time. So a dedicated team representing all functions of our company set out to shift the one-size-fits-all chemotherapy treatment paradigm. Of all the things we accomplished, I am most proud of the financial assistance and access programs that we established allowing patients to focus on making the best possible treatment decision without the burden of financial barriers. Today we can truly say we have made a significant difference in how breast cancer is evaluated and treated."
As Executive Vice President, Worldwide Commercialization David Logan oversees a global team of over 220 people working to deliver personalized medicine to patients by securing reimbursement and physician adoption of Genomic Health’s Oncotype DX tests. Prior to taking this role in 2010, David served as Senior Vice President, Commercial, from 2007 to 2010 and as Vice President of Sales (Managed Care, Operations and Sales) from 2003 through 2007. Under David’s leadership Genomic Health has secured widespread reimbursement for the Oncotype DX breast cancer through contracts, agreements and policy decisions. Before joining Genomic Health, David served in various commercial management roles at Genentech, Inc. including Vice President of Specialty Therapeutics (Sales and Marketing) in 2002 and Senior Director, Director and Management positions in Marketing/Sales, Managed Care and Sales Operations from 1987 to 2002. Prior to joining Genentech, David held positions in sales and sales management at Pfizer Inc. after spending four years in the United States Army. David holds Bachelor of Arts degree in Communications/Marketing from the University of Alabama.
Kathy Hibbs, Senior Vice President & General Counsel
"Patients are central to all we do at Genomic Health and being able to provide doctors and patients with better and more meaningful information, which helps individualize cancer treatment planning, serves as a powerful motivator. I am grateful to have the opportunity to add my skills to the important mission of improving patients’ lives."
Kathy Hibbs brings over 20 years of legal and management expertise to Genomic Health. As Senior Vice President and General Counsel, Kathy is responsible for the Legal, Regulatory and Business Development functions at Genomic Health. Prior to joining Genomic Health in 2010, Kathy served as a Senior Vice President and general counsel at Monogram Biosciences, a developer of products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. During her 2001 through 2009 tenure at Monogram, Kathy was responsible for Legal and Regulatory matters. Prior to that, Kathy held corporate counsel positions for Multitude, Inc., Varian Medical Systems and First Nationwide Bank. Kathy is active in several industry groups including the American Clinical Laboratory Association (ACLA), The Coalition for 21st Century Medicine and The Personalized Medicine Coalition (PMC) and has participated on behalf of industry before panels for both the U.S. President´s Councils of Advisors on Science and Technology and the California Council on Science and Technology. Kathy holds Juris Doctorate from the University of California, Hastings School of Law, and a Bachelors of Arts in Political Science, from the University of California, Riverside. In 2011, Kathy was named as one of the Top Best Bay Area Corporate Counsels and as one of the Bay Area’s Most Influential Women in Business, by The San Francisco Business Times.
Laura Leber, Senior Vice President, Corporate Communications
"It’s thrilling to be part of a company from its early days and to witness a group of smart, passionate people bring a vision to reality, but it is a real privilege to be responsible for telling the world about it. The story of Oncotype DX and the power of personalized medicine is one that has captured a lot of attention. But it wouldn’t have received more than a passing notice if the people of Genomic Health hadn’t insisted on scientific and clinical rigor and on world-class customer support for physicians and patients. And it would not have happened if not for the brave heroes -- the breast and colon cancer patients -- whose stories shape, inform and inspire our work on a daily basis. And best of all, Genomic Health’s story has just begun!"
Laura Leber has led the company’s efforts to tell Genomic Health’s story since 2002. In her current role as Senior Vice President, Corporate Communications, Laura is responsible for global communications to media, investor, patient and employee audiences. Prior to joining Genomic Health, Laura worked in various communications roles at Genentech, Inc., a leading biotechnology company, from 1992 until 2001, most recently as Vice President, Corporate Communications, where she was responsible for the company´s worldwide communications function. Before joining Genentech, Laura held various positions in Corporate Communications and Public Relations for Searle, a pharmaceutical company in Chicago, and at Fleishman-Hillard, Inc. in St. Louis and Hill and Knowlton, Inc. in New York City, both global public relations agencies. Laura holds a Bachelor of Journalism degree from the University of Missouri, Columbia.